Disease burden and quality of life of patients with chronic urticaria in Spain. Prevalence of chronic urticaria refractory to standard therapy in routine clinical practice. UCREX study.

Researchers

A

Albert González Martin

Dermatologist
A

Anna Ravella Matthew

Dermatologist
PhD
D

David Vidal Sarro

Dermatologist
PhD
G

Gisela Hebe Petiti

Dermatologist
J

Joan Antoni Smandia Domínguez

Dermatologist
PhD
L

Laura Peramiquel Fonollosa

Dermatologist

L

Loida Galvany Rosell

Dermatologist
M

Mª Rosa Olivella Garcés

Dermatologist
M

Maria López Nuñez

Dermatologist
M

Maria Villar Buil

Dermatologist
N

Nuria Lamas Domenech

Dermatologist

Contact the group

Form

Martorell A, Alfageme Roldán F, Vilarrasa Rull E, Ruiz-Villaverde R, Romaní De Gabriel J, García Martínez F, Vidal D, Velasco Pastor M, Ciudad Blanco C, Segura Palacios JM, Rodríguez Bandera AI, Pascual Ramírez JC, Sancho Sánchez C, Michelena De Gorosábel N, Wortsman X 113/19

Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicenter study.

J Eur Acad Dermatol Venereol. 2019;33(11):2137-2142.
Del Alcázar E, Ferran M, López-Ferrer A, Notario J, Vidal D, Riera J, Aparicio G, Gallardo F, Vilarrasa E, Alsina M, Puig L, Ferrándiz C, Carrascosa JM. 114/19

Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.

J Dermatologist Treat. 2019;18:1-5.
Vidal D, Alfageme F. 115/19

PAAF and BAG echo-guided in Dermatology: a step forward.

Actas Dermosifiliogr. 2019;110:707-9.
Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcázar E, Carrascosa JM, Corral M, Salleras M, Ribera M, Puig L, Pujol RM, Vidal D, Gallardo F. 116/19

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicenter retrospective study.

J Eur Acad Dermatol Venereol. 2019;33(3):553-559.
Matas-Nadal C, Malvehy J, Ferreres JR, Boada A, Bodet D, Segura S, Salleras M, Azon A, Bel-Pla S, Bigata X, Campoy A, Curcó N, Dalmau J, Formigon M, González A, Just M, Llistosella E, Nogues ME, Pedragosa R, Pujol JA, Sabat M, Smandia JA, Zaballos P, Puig S, Martí RM. 97/19

Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia.

Int J Dermatol. 2019;58(5):577-581.
Martorell A, Alfageme Roldán F, Vilarrasa Rull E, Ruiz-Villaverde R, Romaní De Gabriel J, García Martínez F, Vidal D, Velasco Pastor M, Ciudad Blanco C, Segura Palacios JM, Rodríguez Bandera AI, Pascual Ramírez JC, Sancho Sánchez C, Michelena De Gorosábel N, Wortsman X 113/19

Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicenter study.

J Eur Acad Dermatol Venereol. 2019;33(11):2137-2142.
Del Alcázar E, Ferran M, López-Ferrer A, Notario J, Vidal D, Riera J, Aparicio G, Gallardo F, Vilarrasa E, Alsina M, Puig L, Ferrándiz C, Carrascosa JM. 114/19

Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.

J Dermatologist Treat. 2019;18:1-5.
Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcázar E, Carrascosa JM, Corral M, Salleras M, Ribera M, Puig L, Pujol RM, Vidal D, Gallardo F. 116/19

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicenter retrospective study.

J Eur Acad Dermatol Venereol. 2019;33(3):553-559.
Matas-Nadal C, Malvehy J, Ferreres JR, Boada A, Bodet D, Segura S, Salleras M, Azon A, Bel-Pla S, Bigata X, Campoy A, Curcó N, Dalmau J, Formigon M, González A, Just M, Llistosella E, Nogues ME, Pedragosa R, Pujol JA, Sabat M, Smandia JA, Zaballos P, Puig S, Martí RM. 97/19

Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia.

Int J Dermatol. 2019;58(5):577-581.
Notario J, Deza G, Vilarrasa E, Valentí F, Muñoz C, Mollet J, Rocamora V, Carrascosa J, Alcázar E, Alsina M, Vidal D, Puig L, López-Ferrer A, Riera J, Gallardo F, Ferran M. 29/18

Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.

J Dermatologist Treat. 2018:1-21.

Projects

- Year 2020
- Sant Joan Despí Moisès Broggi Hospital
Implementation of the network of non-melanoma skin cancer centers.
- DISTRICT ATTORNEY:
  
  Dr. Agustín Toll Abe - Melanoma Unit at the Hospital Clínic de Barcelona
- TYPE E:
  
  PINE TREE
- Year 2020
- Sant Joan Despí Moisès Broggi Hospital
Cross-sectional and retrospective study of clinical histories to evaluate the intensity of psoriasis in Spanish patients with moderate to severe psoriasis who routinely receive systemic treatment. CRYSTAL studio.
- DISTRICT ATTORNEY:
  
  AbbVie España SLU
- TYPE E:
  
  EPA-OD
Dermatologist

Researcher
- Year 2019
- Sant Joan Despí Moisès Broggi Hospital
Skin cancer. The exposome paradigm.
- DISTRICT ATTORNEY:
  
  Dr. Tamara García Cazaña from the Barbastro Hospital
- TYPE E:
  
  PI
Dermatologist

Researcher
- Year 2019
- Sant Joan Despí Moisès Broggi Hospital
Observational study to evaluate the descriptive effectiveness in the real world in patients with moderate to severe plaque psoriasis treated with brodalumab”, Estudio BROACTIVE.
- DISTRICT ATTORNEY:
  
  LEO PHARMA SA
- TYPE E:
  
  EPA-SP
Dermatologist

Researcher
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Prospective observational study to evaluate the quality of life in patients with plaque psoriasis treated with Enstilar® for the first time.
- DISTRICT ATTORNEY:
  
  LEO Pharmaceutical Products Ltd
- TYPE E:
  
  EPA-SP
Dermatologist

Researcher
- Year 2019
- Sant Joan Despí Moisès Broggi Hospital
I study SPRING. Multicenter retrospective study of routine clinical practice in patients with moderate to severe psoriasis treated with Guselkumab.
- DISTRICT ATTORNEY:
  
  Janssen‐Cilag SA
- TYPE E:
  
  EPA-OD
- Year 2019
- Sant Joan Despí Moisès Broggi Hospital
Skin cancer. The exposome paradigm.
- DISTRICT ATTORNEY:
  
  Dr. Tamara García Cazaña from the Barbastro Hospital
- TYPE E:
  
  PINE TREE
- Year 2019
- Sant Joan Despí Moisès Broggi Hospital
Observational study to evaluate the descriptive effectiveness in the real world in patients with moderate to severe plaque psoriasis treated with brodalumab", Estudio BROACTIVE.
- DISTRICT ATTORNEY:
  
  LEO PHARMA SA
- TYPE E:
  
  EPA-SP
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Prospective observational study to evaluate the quality of life in patients with plaque psoriasis treated with Enstilar® for the first time.
- DISTRICT ATTORNEY:
  
  LEO Pharmaceutical Products Ltd
- TYPE E:
  
  EPA-SP
- Year 2019
- Sant Joan Despí Moisès Broggi Hospital
I study SPRING. Multicenter retrospective study of routine clinical practice in patients with moderate to severe psoriasis treated with Guselkumab.
- DISTRICT ATTORNEY:
  
  Janssen‐Cilag SA
- TYPE E:
  
  EPA-OD

Lines of action

Immune mediated skin diseases
Skin cancer
neurofibromatosis
Ultrasonography

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR cookie consent plugin, this cookie is used to record the user's consent to cookies in the "Ad" category.
cookielawinfo checkbox analytics	1 year	Set by the GDPR cookie consent plugin, this cookie is used to record the user's consent to cookies in the "Analytics" category.
cookielawinfo checkbox functional	1 year	The cookie is set by the GDPR cookie consent plugin to record the user's consent to cookies in the "Functional" category.
cookielawinfo-checkbox-Necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-fastrs	1 year	Set by the GDPR cookie consent add-on, this cookie is used to store the user's consent to cookies in the "Other" category.
cookielawinfo checkbox performance	1 year	Set by the GDPR cookie consent add-on, this cookie is used to store the user's consent for cookies in the "Performance" category.
CookieLawInfoConsent	1 year	Record the default button state of the corresponding category & the CCPA state. It only works in coordination with the main cookie.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also tracks site usage for the site analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_5515H28R8E	2 years	This cookie is installed by Google Analytics.

Dermatologist

Disease burden and quality of life of patients with chronic urticaria in Spain. Prevalence of chronic urticaria refractory to standard therapy in routine clinical practice. UCREX study.

Researchers

Albert González Martin

Anna Ravella Matthew

David Vidal Sarro

Gisela Hebe Petiti

Joan Antoni Smandia Domínguez

Laura Peramiquel Fonollosa

Loida Galvany Rosell

Mª Rosa Olivella Garcés

Maria López Nuñez

Maria Villar Buil

Nuria Lamas Domenech

Contact the group

Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicenter study.

J Eur Acad Dermatol Venereol. 2019;33(11):2137-2142.

Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.

J Dermatologist Treat. 2019;18:1-5.

PAAF and BAG echo-guided in Dermatology: a step forward.

Actas Dermosifiliogr. 2019;110:707-9.

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicenter retrospective study.

J Eur Acad Dermatol Venereol. 2019;33(3):553-559.

Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia.

Int J Dermatol. 2019;58(5):577-581.

Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicenter study.

J Eur Acad Dermatol Venereol. 2019;33(11):2137-2142.

Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.

J Dermatologist Treat. 2019;18:1-5.

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicenter retrospective study.

J Eur Acad Dermatol Venereol. 2019;33(3):553-559.

Increasing incidence of lentigo maligna and lentigo maligna melanoma in Catalonia.

Int J Dermatol. 2019;58(5):577-581.

Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.

J Dermatologist Treat. 2018:1-21.

Projects

Implementation of the network of non-melanoma skin cancer centers.

DISTRICT ATTORNEY:

Dr. Agustín Toll Abe - Melanoma Unit at the Hospital Clínic de Barcelona

TYPE E:

PINE TREE

Cross-sectional and retrospective study of clinical histories to evaluate the intensity of psoriasis in Spanish patients with moderate to severe psoriasis who routinely receive systemic treatment. CRYSTAL studio.

DISTRICT ATTORNEY:

AbbVie España SLU

TYPE E:

EPA-OD

Dermatologist

Researcher

Skin cancer. The exposome paradigm.

DISTRICT ATTORNEY:

Dr. Tamara García Cazaña from the Barbastro Hospital

TYPE E:

PI

Dermatologist

Researcher

Observational study to evaluate the descriptive effectiveness in the real world in patients with moderate to severe plaque psoriasis treated with brodalumab”, Estudio BROACTIVE.

DISTRICT ATTORNEY:

LEO PHARMA SA

TYPE E:

EPA-SP

Dermatologist

Researcher

Prospective observational study to evaluate the quality of life in patients with plaque psoriasis treated with Enstilar® for the first time.

DISTRICT ATTORNEY:

LEO Pharmaceutical Products Ltd

TYPE E:

EPA-SP

Dermatologist

Researcher

I study SPRING. Multicenter retrospective study of routine clinical practice in patients with moderate to severe psoriasis treated with Guselkumab.

DISTRICT ATTORNEY:

Janssen‐Cilag SA

TYPE E:

EPA-OD

Skin cancer. The exposome paradigm.

DISTRICT ATTORNEY:

Dr. Tamara García Cazaña from the Barbastro Hospital

TYPE E:

PINE TREE

Observational study to evaluate the descriptive effectiveness in the real world in patients with moderate to severe plaque psoriasis treated with brodalumab", Estudio BROACTIVE.